The study will begin with the administration of the mDCF chemotherapy regimen, followed by treatment with Ezabenlimab. After this, patients will receive chemoradiotherapy, which is a combination of chemotherapy and radiation therapy. This approach aims to enhance the effectiveness of the treatment by using different methods to target the cancer cells. The study will monitor patients over a period to assess the response to the treatment and any side effects that may occur.

Throughout the study, various assessments will be conducted to evaluate the effectiveness of the treatment. These include imaging tests like MRI and PET scans to check for any remaining cancer. The study will also look at the overall survival of patients, which is the time from the start of treatment until death from any cause, and progression-free survival, which is the time during which the cancer does not get worse. Additionally, the study will assess the quality of life of patients during and after the treatment. Safety will be closely monitored by checking for any adverse effects or changes in health status.

The purpose of this study is to evaluate how effective these treatments are in preventing the cancer from getting worse over a period of one year. Participants in the study will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, and participants will be monitored regularly to assess their response to the treatment and to check for any side effects.

Throughout the study, participants will undergo various tests and scans, such as a CT scan or MRI, to help doctors see how the cancer is responding to the treatment. The goal is to find out if this combination of treatments can help control the cancer and improve the quality of life for patients with this type of cancer. The study will also help researchers understand more about the safety and effectiveness of these treatments when used together.

The treatment involves receiving pembrolizumab as an infusion at a dose of up to 200 mg, along with vorinostat capsules at a dose of up to 400 mg daily. The treatment period may continue for up to 105 weeks. During the study, doctors will monitor how the cancer responds to the treatment combination through regular medical examinations and imaging tests.

Both medications work differently to fight cancer. Pembrolizumab is an immunotherapy drug that helps the body’s immune system recognize and attack cancer cells. Vorinostat belongs to a group of medications that work by affecting how genes behave in cancer cells. This combination approach aims to provide better results than using either medication alone.

The purpose of the study is to determine if this combination of treatments is effective in treating patients with localized squamous cell carcinoma of the anal canal. The study will involve patients receiving these treatments over a period of time, and their progress will be monitored to see if the cancer goes into remission. The study will also look at other outcomes, such as how long patients remain free of cancer, their overall survival, and any side effects they may experience.

Participants in the study will receive the treatments as a solution for infusion, which means the medication is given directly into the bloodstream through a vein. The study will last for several months, and patients will have regular check-ups to monitor their health and the effectiveness of the treatment. The goal is to see if this new combination of treatments can improve outcomes for patients with this type of cancer.

The purpose of the study is to determine if starting treatment with chemotherapy, followed by radiation therapy, is more effective than just using radiation therapy alone. Participants in the study will receive either the combination of chemotherapy and radiation or just the standard radiation therapy. The study will last for a period of time, during which the health of the participants will be closely monitored. The researchers aim to see if the combination treatment helps patients live longer without the cancer coming back or getting worse.

Throughout the study, participants will undergo regular check-ups and tests, such as MRI scans, to monitor the progress of the treatment. The study will also look at other factors, such as overall survival, quality of life, and any side effects experienced by the participants. The goal is to find the best treatment option for people with this type of cancer, helping them to have a better quality of life and improved outcomes.

The purpose of the study is to evaluate the safety and effectiveness of combining pelareorep and atezolizumab with standard chemotherapy treatments. Participants will receive these treatments and be monitored for their response to the therapy. The study will assess how well the combination of these drugs works in treating the cancer and how well patients tolerate the treatment. The study will also look at the overall response rate, which measures how the cancer responds to the treatment, and the disease control rate, which indicates how well the treatment keeps the cancer from growing or spreading.

Throughout the study, participants will undergo regular assessments to monitor their health and the effects of the treatment. These assessments will include checking for any side effects and measuring the size of the cancer to see how it responds to the treatment. The study aims to provide valuable information on the potential benefits of using pelareorep and atezolizumab together with standard chemotherapy for treating advanced gastrointestinal cancers.